This article was originally published in The Gray Sheet
Orthopedic and cardiovascular firm's spin-off from parent Sulzer AG completed July 10 following shareholder approval July 9, despite uncertainties over uninsured costs of the recall of its Inter-Op hip shells and related lawsuits (1"The Gray Sheet" June 4, 2001, In Brief)
You may also be interested in...
Spin-off of medical device unit from parent Sulzer Ltd. is slated for July 10 following shareholder meeting on July 9. Following spin-off, the parent will retain a 4% stake in firm. Sulzer management first announced its spinout plan March 9 on the heels of a hostile takeover bid from investor group InCentive Capital. The bid has since failed (1"The Gray Sheet" March 12, 2001, p. 27). Firm also announces appointment of Stephen Rietiker as CEO of the Medica unit, effective August 1. Rietiker, formerly VP and general manager of Covance, replaces current CEO Andre Buchel, who will retire
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.